Evidence map›Paper›PMID 42366866›Full record

ArticleNephrology (Carlton, Vic.)2026

Optimising Therapeutic Target Attainment in Vancomycin Therapy for Patients Requiring Intermittent Haemodialysis.

Danny Tsai, María Patricia Hernández-Mitre, Amy Legg, Jacqueline Martin, Cherian Sajiv, Sachin Kodgire, William Naughton, Sonja Janson, Jaquelyne T Hughes, Xin Liu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nephrology (Carlton, Vic.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Danny TsaiFlinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Darwin, Northern Territory, Australia.
María Patricia Hernández-MitreUQ Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.
Amy LeggUQ Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.
Jacqueline MartinPharmacy Department, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.
Cherian SajivDepartment of Nephrology, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.
Sachin KodgireDepartment of Nephrology, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.
William NaughtonDepartment of Medicine, Alice Springs Hospital, Alice Springs, Northern Territory, Australia.
Sonja JansonDepartment of Infectious Diseases, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
Jaquelyne T HughesFlinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Darwin, Northern Territory, Australia.ORCID https://orcid.org/0000-0002-1867-4156
Xin LiuUQ Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.
Jason A RobertsUQ Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.

Funding

Australian National Health and Medical Research Council APP2007007Australian National Health and Medical Research Council APP2009736Australian National Health and Medical Research Council GNT1174758The Hospital Research Foundation CF-EMCR-106-83100
6 · The paper itself

Abstract

aimsTo describe the pharmacokinetics of vancomycin in patients requiring intermittent haemodialysis (iHD) and provide guidance for optimised dosing for a three-times-weekly post-iHD regimen.

methodsA population pharmacokinetic study using retrospectively collected data was conducted in a remote Australian dialysis centre. Adult patients receiving post-iHD vancomycin therapy between 1st January 2017 and 31st July 2023 were screened. INCLUSION CRITERIA: ≥ 3 months of iHD, prescribed vancomycin, and recorded ≥ 1 vancomycin concentration. Pharmacokinetic analysis was performed using Monolix. The probability of pharmacokinetic/pharmacodynamic target attainment (PTA) for pre-iHD trough concentrations of 15-20 mg/L was simulated for various loading and maintenance doses.

resultsA total of 302 vancomycin concentrations were available from 80 courses (58 patients, 45 were female) with a median age of 52 (IQR 45-61) years and weight of 75 (66.5-85.5) kg. A one-compartment model adequately described the data. Actual body weight was the only covariate retained in the final model. The estimated vancomycin clearance during non-iHD periods, during iHD periods, and volume of distribution were 0.54 L/h, 4.84 L/h, and 87.02 L, respectively. The simulations supported weight-based loading doses. The time to the next iHD session also significantly influenced the PTA of loading doses. Subjects with higher weight required lower weight-based doses, and vice versa. The PTA of maintenance doses was associated with the pre-iHD trough concentrations and the dosing intervals. Weight had a limited impact on the PTA of maintenance doses.

conclusionA comprehensive vancomycin dosing nomogram was suggested for patients requiring iHD. Validation in future prospective studies is recommended.

Indexed as

Anti-Bacterial AgentsRenal DialysisVancomycinFemaleHumansMaleMiddle AgedRetrospective StudiesAnti-Bacterial AgentsVancomycindosingintermittent haemodialysispharmacokineticsvancomycin

Identifiers

PMID42366866
PMCPMC13312042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.